Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 5/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | BCL6 | P41182 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318276 | 0.83 | — | — | |
| SCHEMBL12336950 | 0.79 | TLR8 (0.47) | NUDT1HRH4HRH3CDK5CDK5R1 | |
| SCHEMBL8127847 | 0.79 | HRH4 (0.42) | NUDT1HRH4HSP90AA1AURKAPRKACA | |
| SCHEMBL28749703 | 0.78 | HRH3 (0.51) | NUDT1HRH4HSP90AA1AURKAPRKACA | |
| SCHEMBL4273110 | 0.77 | SORD (0.42) | NUDT1 | |
| SCHEMBL12439674 | 0.76 | NUDT1 (0.51) | NUDT1HRH4HSP90AA1AURKAPRKACA | |
| SCHEMBL12514073 | 0.76 | TLR8 (0.53) | NUDT1HRH4HRH3TLR8NPC1 | |
| Ammonia Solution, Strong SCHEMBL5846083 | 0.76 | HRH3 (0.50) | NUDT1HRH4HSP90AA1AURKAPRKACA | |
| SCHEMBL17379406 | 0.76 | — | — | |
| SCHEMBL2018150 | 0.75 | RECQL (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240383863-A1 | PREPARATION METHOD FOR PYRIMIDINE-2-AMINE | INSTITUTE FOR BASIC SCIENCE (KR) | 2024-11-21 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383863-A1 | PREPARATION METHOD FOR PYRIMIDINE-2-AMINE | NUDT1, UMPS, DPYD | NUDT1 1/4885HRH4 1014/4885HSP90AA1 4541/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | NUDT1 1955/4885HRH4 4286/4885HSP90AA1 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.